Before the advent of the acquired immune deficiency syndrome (AIDS), blood transfusion was felt to be an almost benign process and the use of blood products increased steadily, to the point where blood component preparation could barely keep pace with increasing demand for blood products. Then, AIDS modified the perception of the safety of blood dramatically, both for physicians and patients, resulting in major changes in the use of blood products between 1980 and 1985. 2 The extent of this concern with the complications secondary to the transfusion of blood products is well illustrated by the number of texts published on the subject in recent years. [3] [4] [5] [6] The objectives of this refresher course are to (1) Review briefly the infective complications associated with blood transfusions, (2) Re-examine the indications for homologous blood products (HBP), and (3) Discuss some of the alternative strategies available to decrease or avoid the transfusion of HBP altogether. Special attention will be given, throughout the text, to the Canadian situation.
Infective complications of blood transfusion
The numerous complications of homologous blood transfusions have been reviewed extensively 3,4 and are presented in Table I . The infective risk of blood transfusions appears to have declined recently as a result of screening policies for donated blood (Table II) implemented by the Blood Services of The Canadian Red Cross Society. 7 In general, bacterial contaminants do not present a problem, except in platelet components which are stored at room temperature and for Yersinia enterolitica for which the storage temperature of 4~ is not as bacteriostatic as with other genera. Parasites are not a severe problem in Canada. Despite the awareness surrounding the transmission of AIDS by transfusion, the commonest infection associated with HBP is posttransfusion hepatitis (PTH); hepatitis A virus, cytomegalovirus and EpsteinBarr virus seldom cause PTH.
In the U.S.A., the frequency of PTH with the hepatitis B virus is estimated to be 1 in 50,000 per recipient or approximately 1 in 200,000 per unit. 8 Ninety percent have a self-limited .course (the majority, asymptomatic), five to ten percent will progress to a chronic state (half become asymptomatic carriers), and 1% will have a fulminant form of hepatitis (mortality >50%). In Canada, the numbers are similar. During the past three years, only one case of Hepatitis B-PTH has been reported by the Montreal Blood Centre for 900,000 blood products transfused (Gilles Delage, Canadian Red Cross Society Blood Centre in Montrral, personal communication). Assuming that only 25% of infections are symptomatic, this results in an infection rate similar to that reported in the U.S.A.
Hepatitis C virus (HCV) is the agent responsible for most, but probably not all, cases of non A/non B PTH. As for hepatitis B, the incidence of HCV associated PTH varies according to the population studied. Again, in Canada, the infection rate appears to be similar to that in the U.S.A. (Gilles Delage, personal communication), i.e., approximately-1 in 3000 blood components transfused. 9 Hepatitis C posttransfusion hepatitis has a mild presentation initially, but 50% of patients progress to a chronic state (persistent carrier stage) and 10-20% of these develop cirrhosis.
In 1992, Crosby reported that presently only two HIV conversions (from 15 million units of blood products administered) have been associated with transfusions since the implementation of HIV screening in 1985 in Canada. 3 The commonly used screening technique is based on the detection of antibodies to the HIV virus. Antibody negativity lasts eight weeks on average after infection, but seroconversion may be delayed for up to 42 mo. Therefore, a few contaminated units will continue to escape detection despite systematic screening. I~ Nevertheless, with the present selection of donors and testing of blood, the risk of HIV transmission by blood transfusion is estimated between 1/40,000 to 1 / 1,000,000. H Both HTLV-1 and HTLV-2 may cause leukaemia, lymphoma, tropical spastic paraparesis and HTLV-I associated myelopathy. In Northern America, the transmis- sion of HTLV is infrequent and the associated risks are difficult to assess at present.
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Overall, it has been suggested that about 3 in 10,000 blood recipients contract serious or fatal viral disease transmitted by transfusion, s As stated by the Canadian Red Cross Society, "transfusion of blood and blood products is associated with certain risks that cannot be predicted or prevented. The physician should prescribe transfusion only when it is clinically essential and when no other form of treatment would be as effective."7
Indications for homologous blood products
One unit of whole blood (450 ml in 63 ml of anticoagulant) is separated into components within four to six hours of donation. Separation allows each component to be stored under optimal conditions and patients can be administered only that portion of blood required by their condition, allowing several patients to benefit from a single donation. Of all the components derived from whole blood and available from the Red Cross (Table III) , red blood cells (RBC), fresh frozen plasma (FFP) and platelets are, in essence, the only HBP that are administered commonly by anaesthetists and carry an infectious potential. The indications for these HBP will be reviewed on the basis of the Consensus Development Conferences convened by the Office of Medical Applications of Research, of the National Institutes of Health (USA). J z- 13 
Indications for the transfusion of RBC
Red blood cells are prepared by removing supernatant plasma from a whole blood donation after centrifugation. One unit of RBC contains 200 ml of red cells, with either the anticoagulant CPDA-I or CP2D and 100 ml of the additive AS-3 (Nutricel(~), and 90 or 60 ml of plasma, respectively. Shelf life is 35 days at 1~176 but RBC with AS-3 have the potential for 42 days shelf life. Isotonic saline may be added to either preparation to increase the flow of RBC. Red blood cells must be administered through a 170 Izg fdter.
The Conference recognizes there is no evidence to support the use of a single criterion for transfusion, such as a haemoglobin concentration of < 100 g. L -I. "The decision to transfuse a specific patient should take into consideration the duration of anaemia, the intravascular volume, the extent of operation, the probability for massive blood loss, and the presence of coexisting conditions such as impaired pulmonary function, inadequate cardiac output, myocardial ischaemia, or cerebrovascular or peripheral circulatory disease."tl The need for research to defme the best indications for red blood cell transfusion is acknowledged. While "no single measure can replace good clinical judgment as the basis for decisions regarding perioperative transfusion, "t~ is it possible to refine our criteria for transfusion of RBC any further?.
The dominant role of RBC is the transport and delivery of oxygen from alveoli to cells. In acute blood loss, it is well accepted that volume replacement is more critical than the composition of the replacing fluids. Thus, RBC should not be administered for volume replacement alone, but only for the anaemia and decreased oxygen carrying capacity of the blood that accompanies severe haemorrhage. While transfusion of RBC is used to increase tissue oxygen delivery (DOz), effective DO2 is dependent on the cardiovascular condition of the patient also. Higher than normal values for cardiac index and tissue oxygen consumption (VOz) are other important determinants of survival in patients with medical or surgical shock. 14 During normovolaemic haemodilution (anaemia without hypovolaemia) blood viscosity decreases as the haematocrit is reduced and, between haematocrits of 28 and 45%, DO2 remains relatively constant, s When the haematocrit is decreased further, VO2 is maintained within normal limits by increasing either the cardiac output or the oxygen extraction ratio (ER). The increase in ER is somewhat limited by an already high ER in the cerebral and coronary circulations (55-70% vs 25% total body ER) but, during progressive normovolaemic haemodilution in baboons, the global oxygen ER must exceed 50% for the myocardium to switch from lactate consumption to lactate production. 15 Older patients and patients with coronary artery disease may not be able to increase cardiac output to compensate for anaemia.S When compensatory mechanisms are no longer adequate, ~/O2 decreases and tissues survive by anaerobic metabolism.
In their extensive review of the literature since 1966, Welch et al. noted the remarkable tolerance of healthy patients to low haemoglobin concentrations (between 50 and 70 g" L-~), and suggested that clinicians can accept haemoglobin levels >70 g. L -l in most patients with selflimited anaemia. 16 The conclusions of the Consensus Conference on perioperative red blood cell transfusion are not as explicit, but their findings point to the same recommendation." The ASA Committee on Transfusion Medicine states that postoperative haemoglobin concentrations in the 60 to 80 g. L -I range appear to be safe for patients free of cardiovascular disease. =7 However, it must be recognized that the margin of safety for DO2 diminishes as haemoglobin concentrations decrease and patients with severe cardiovascular disease may not tolerate haemodilution below a haemoglobin value of 80 to 100 g. L -I. ~7,~8 Nevertheless, the effects of transfusion for anaemia on myocardial oxygen metabolism are not limited to the correction of the decreased oxygen supply, and clinicians must also take into account the possible aggravation of ischaemia by increasing blood volume, afterload, and blood viscosity. 16 Haemodilution to an haematocrit of approximately 15% is well tolerated in anaesthetized humans,after coronary artery bypass surgery, with no ECG or metabolic evidence of myocardial ischaemia. 19 The absolute concentration of haemoglobin is not the only indicator of the need for transfusion of RBC. Surgical blood loss is also a strong and independent predictor of outcome. In a study of 125 patients who declined blood transfusion for religious reasons, no patient with a haemoglobin value of >80 g" L -I and an operative blood loss of <500 ml died. Mortality increased from 8% to 43% as blood loss increased from less than 500 ml to over 2000 ml despite maintenance of an adequate circulating volume. 2o
The efficacy of RBC transfusion should be monitored since the oxygen content of blood is not the only de-R55 terminant of DO 2 and VO2. It is interesting to note that, in dogs, moderate haemodilution to an haematocrit of 20 or 30% is associated with an improvement of the 02 extraction capabilities of the body (lower critical DO2 and higher critical 02 extraction ratio) during haemorrhage, compared with haemorrhage at an haematocrit of 40%. 2~ A useful endpoint to guide appropriateness of RBC administration is the increase of VO2 in response to transfusion. A practical limitation of this recommendation is that measurement of "v'O2 entails the use of invasive haemodynamic monitoring. However, increasing blood lactate concentration is an early indicator of inadequate perfusion and evidence of an oxygen debt. With the newer automated blood gas analysers, serum lactate levels are readily available and provide a valid and minimally invasive marker of anaerobic metabolism. An abrupt increase in blood lactate levels is observed when DO2 decreases below the critical DO2 value. 2! Thus, lactate levels may prove to be a useful indicator of the need for adequacy of RBC transfusions, at least in certain patient subgroups. 22 Another, less well known, function of red cells is to increase the platelet-to-platelet interaction and facilitate the interaction of platelets with the subendothelium. Transfusion of RBCs normalizes the bleeding time in anaemic-thrombocytopaenic patients despite persistent thrombocytopaenia. 23 Similarly, RBCs control the haemorrhagic diathesis and shorten the bleeding time of uremic patients. 24 Thus a haemoglobin concentration acceptable for maintenance of DO2 may not be sufficient to achieve optimal haemostasis. This may help to explain' why, after cardiopulmonary bypass (CPB), the haemostatic effect of a single unit of fresh whole blood is at least equal, if not superior, to the effect of ten units of platelets. 2s
Indications for transfusion of platelets z13 '17 In the anaesthetic/surgical setting, platelet concentrates are the second most useful HBP after RBC. One unit of platelets is obtained following centrifugation of one unit of fresh whole blood. Platelets are concentrated in 30-50 ml of plasma and the fmal product contains a small number of leucocytes and RBC (up to 0.4 ml per unit). Storage at room temperature (20~176 preserves function and slow constant horizontal agitation prevents the formation of platelet aggregates. Storage is restricted to five days to limit the growth of any contaminating bacteria. In the normal adult, administration of one unit of platelet concentrate increases the platelet count by 5-10 X 10 9. L -1 one hour after transfusion. Thus, the usual dose consists of six to eight units of platelets and exposes the recipient to an equivalent number of donors. Platelet units can be mixed in a single bag prior to administration (but must then be administered within six hours), and use of a standard 170 ~tm filter is recommended. Administration of ABO incompatible platelets is an accepted practice. Even with the administration of ABO compatible platelets, the possibility of Rh immunization must be considered in female patients of child-bearing age. Red cell haemolysis may also occur when large numbers of ABO incompatible platelet concentrates are transfused. Special circumstances may dictate the use of platelets obtained from random or HLA-matched single donors.
Patients with severe thrombocytopaenia may benefit from platelet transfusion to prevent bleeding. The empirical value of 20 X 10 9 platelets-L -~ is usually considered adequate in the medical setting. Patients with chronic thrombocytopaenia generally do not require routine platelet transfusions but may benefit from prophylactic administration of platelets prior to surgery or other invasive procedures. Consultation with a haematologist is suggested to determine the optimal platelet count for each patient since, for example, other options such as administration of immunoglobulins/v may normalize the platelet count in idiopathic thrombocytopaenic purpura.
As a general rule, blood components administered to improve haemostasis, such as platelet concentrates and FFP, should never be given for abnormal laboratory studies in the absence of clinical bleeding. Patients with thrombocytopaenia and/or an abnormality of platelet function who are bleeding should receive platelets, if the platelet disorder is likely to be causing or contributing to the bleeding. ~3 A reasonably accurate platelet count may be obtained very rapidly with an automated blood counter. In the absence of platelet dysfunction, a platelet count of 50 X 10 9. L -1 or higher is unlikely to be responsible for active bleeding. Evaluation of platelet function is much more difficult and, at present, there is no consensus as to the ideal method of evaluation. Appearance of the surgical wound, template bleeding time, thromboelastography, and analysis of the Sonoclot Signature@ may provide some indication of platelet function.
Massive transfusion is usually defined as the acute administration of more than one blood volume within several hours and may lead to coagulopathy characterized by microvascular bleeding (a typical, generalized oozing), usually after transfusion of 15-20 units of RBCs in previously healthy adults. 26.27 In order of frequency, coagulation defects result from (1) Loss of platelets and, very rarely, labile factors V and VIII; (2) Disseminated intravascular coagulation (DIC) associated with shock; and (3) Haemolytic transfusion reactions. J3 Platelet release by the spleen and bone marrow helps to prevent dilutional thrombocytopaenia but, in the presence of microvascular bleeding, a platelet count of <50 to 100 X 10 9. L -I can be considered an indication for platelet transfusion. 26,27
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The indications for transfusion of platelets after CPB are not any different and there is no justification for the prophylactic administration of platelets in patients undergoing open heart surgery.
When bleeding does not resolve with platelet transfusion, the next logical step is to administer FFP. 28 
Indications for the transfusion of FFP z12.17
After platelets have been separated, the remaining platelet-poor plasma is rapidly frozen to prevent inactivation of temperature sensitive ("labile") coagulation factors V and VIII. One unit of FFP has a volume of 190-260 ml and is stored at a temperature of <-18~ Few specific indications for the use of FFP exist. There is no justification for the use of FFP for volume replacement or for nutritional support. There is no evidence that FFP has a beneficial effect when used as part of the transfusion management of patients with massive haemorrhage.
Fresh frozen plasma contains all the coagulation factors found in plasma, at a level of activity close to normal, and is indicated for the treatment of isolated factor deficiencies when specific component therapy is either unavailable or inappropriate. Consultation with a haematologist is recommended to determine the most appropriate therapy in this context.
The functional deficiencies induced by oral anticoagulants can be reversed by vitamin K but, when these patients bleed actively or present for emergency surgery, FFP can be used to achieve immediate haemostasis. Subcutaneous vitamin K will take 6 to 24 hr to normalize the coagulation defect. Fresh frozen plasma may be efficacious in massively transfused patients who are bleeding actively, when factor deficiencies are thought to be contributing to the coagulopathy. However, in this situation, clinicians must acknowledge that haemorrhage is caused more frequently by thrombocytopaenia. The Consensus Conference recognized that circumstances exist in which FFP has been employed and is believed to be of therapeutic value (e.g., multiple coagulation protein deficiencies in the uncontrollably bleeding patient), but data supporting its efficacy are limited or unavailable. Again, there is no evidence to support the prophylactic administration of FFP in patients receiving multiple RBC transfusions.
Finally, FFP may be useful as a source of antithrombin III, for the treatment of specific immunodeficieneies, and for the treatment of thrombotic thrombocytopaenic purpura.
In the presence of active bleeding, when FFP is indicated, large volumes (four to eight units) given rapidly are necessary to result in clinically important increases in serum levels of coagulation factors. 29 In the absence CANADIAN JOURNAL OF ANAESTHESIA 
Avoiding homologous blood products
Numerous strategies have been explored and are recommended to decrease or eliminate the need for transfusion of HBP (Table IV) . Some are relatively benign, but others carry risks that must be weighed against those involved when transfusing HBP to a given patient population.
Preoperative strategies
Nonsteroidal anti-inflammatory drugs (NSAID), 90 acetylsalicylic acid (ASA), aj and perhaps some calcium channel antagonists, 32 are associated with increased post-R57 operative bleeding and should be discontinued, if possible, before elective surgery, or replaced by agents with short half-lives whenever possible. Recombinant human erythropoietin is being used currently to treat patients with renal failure and other diseases that result in chronic anaemia. Preoperative administration of erythropoietin, in combination with autologous blood predonation, reduces transfusion of HBP in patients undergoing cardiac operations. 33,34 Erythropoietin is expensive and side effects such as hypertension and hyperviscosity are of concern. It has been recommended that its use be limited to patients who are anaemic before donation (haematocrit <36%) or who are of low body weight (< 52 kg). 35 In addition to augmenting the level of circulating erythrocytes, erythropoietin may help prevent the impairment of immune function that occurs after cardiac surgery. 36 Given the risks associated with HBP, it has been suggested that informed consent be obtained before transfusion, 37 but opinions differ about the advisability of obtaining a written informed consent. 17 Certainly, the anaesthetist should document in the anaesthesia record the indications for administration of blood products. 17 In California, the Paul Gann Blood Safety Act mandates that patients be informed of the risks of blood transfusion and alternatives to it. The Act appears to have prompted increased attention to currently available methods of blood salvage and conservation, lessened blood losses through improved surgical technique, and resulted in reduced transfusion of HBP in patients undergoing cardiac surgery. 38
Approaches to reduce blood loss intraoperatively
Intraoperatively, a number of techniques have long been available to reduce blood loss. These include application of a tourniquet, local infdtration with an epinephrinecontaining solution, optimal venous drainage of the operative site, controlled hypotension and, most important of all, meticulous surgical technique. It has also been shown that variable stress control by anaesthesia may modify haemostasis in cardiac surgical patients, but the effects on blood loss and requirements for HBP remain unclear. 39 Another important, less emphasized, measure to reduce blood loss through preservation of haemostasis is the maintenance of normothermia. Hypothermia causes a reversible platelet dysfunction and rewarming improves platelet function and reduces both bleeding time and blood loss after CPB. 4~ The same authors suggested that rewarming should be attempted before administering HBP in hypothermic bleeding patients, whether it be after CPB, operation, or trauma. 40 Also, hypothermia strongly inhibits the enzymatic reactions of the coagulation cascade and, in the presence of a bleeding patient, this additional contribution of hypothermia to the haemorrhagic diathesis may be overlooked since coagulation testing is performed at 37 ~ C. 41 Pharmacological reduction of bleeding associated with surgery, especially with CPB, has received much attention. 42,43 It has the advantage of being readily available and easy to administer, of avoiding the use of costly equipment, and it may be used prophylactically rather than therapeutically in some instances. Desmopressin (DDAVP), a vasopressin analogue, epsilon-aminocaproic acid (EACA) and tranexamic acid (TA), two synthetic antifibrinolytics, and aprotinine (Apt), an antifibrinolytic derived from bovine lung, have been used either to dirninish or to prevent excessive bleeding associated with cardiac and other major, complicated, surgery.
In 1986, Salzman et al. demonstrated a reduction of blood loss after cardiac surgery by DDAVP in a doubleblind, prospective, placebo-controlled, randomized trial. ~ Numerous subsequent studies by different authors using a similar protocol have failed to reproduce these results. A likely explanation is that blood loss in the original study was excessively high and that Salzman's results may not be generalized to other centres where blood loss is much lower. While thromboelastographic assessment of coagulation may help to identify a subgroup of patients where DDAVP is likely to be efficacious, 45 the usefulness of DDAVP in cardiac surgery is still a subject of controversy. 46,47 Similarly, there is no agreement as to the efficacy of DDAVP to reduce surgical bleeding in patients undergoing spinal fusion for scolJosis. 48,49 Furthermore, DDAVP seems to carry a risk of thrombosis and it should be used cautiously in elderly patients and in those with atherosclerosis. 50,5~
The prophylactic administration of EACA and TA has been restricted largely to cardiac surgery and haemophiliac patients undergoing minor surgical procedures. Retrospective data collected on 411 patients at the Toronto Hospital show that 10 g TA reduced post-CPB bleeding in the first 24 hr prevented excessive bleeding (>750 ml in six hours), and reduced the number of patients receiving HBP. s2 Other data from the same institution demonstrated that TA, EACA and normothermic perfusiOn are equally effective in reducing postoperative blood loss and in preserving platelets, s3 Thus, more data are necessary to define the optimal dose and the clinical effectiveness of these drugs in cardiac surgery. Both EACA and TA are equally effective to treat fibrinolysis and control the bleeding diathesis associated with liver transplantation, but the prophylactic use of these agents is not recommended, to avoid thrombotic complications. 54 Aprotinin is a polypeptide of 58 amino acid residues which inhibits a wide range of serine proteases. In addi-tion to the antiplasmin (antifibrinolytic) action it shares with EACA and TA, aprotinin also inhibits kallikrein and the stimulation of the coagulation cascade secondary to the liberation of tissue plasminogen activator. This dual action of aprotinin is thought to be responsible for its generally accepted efficacy in cardiac surgery. 42 It has also been used successfully in the management of abruptio placentae with disseminated intravascular coagulopathy, s5 to prevent rebleeding after subaraehnoid haemorrhage,56 and to reduce bleeding after orthopaedic [John Murkin, personal communication] and vascular surgery. 57 Many centres are now administering routinely prophylactic aprotinin in high doses (2 million KIU loading dose, followed by an infusion of 500,000 KIU. hr -1) to reduce pefioperative bleeding and HBP requirement during liver transplantation ss,s9 and cardiac surgery (two million KIU are also added to the priming fluid of the CPB circuit). ~~ Administration of aprotinin may be associated with minor allergic responses or anaphylaxis, especially when administration is repeated, but the risk is small (< 1%). 61 Despite fears that high doses of aprotinin may increase thrombotic complications, the safety record of aprotinin, to date, is impressive. 62, 63 Measures to decrease the risks of anaemia These are well known to anaesthetists and do not warrant a more detailed discussion. They can alleviate the physiological consequences of anaemia while confirmatory evidence for the need to transfuse is being sought.
Perioperative alternatives to homologous red cells
Despite all efforts to reduce blood loss, transfusion of red cells may become necessary but, even then, a number of strategies may decrease the need for homologous blood. First, those who order transfusions should do so mindfully rather than automatically, in response to a pathophysiological trigger. Attention to a set of arbitrary criteria rather than to the patient's needs explains the great variability of transfusion practice in coronary bypass surgery. 64 "The patients know this (practice) is not acceptable; we must realize it too. Blood and blood products should be given only when there are clear indications. "65 It follows that all those who order transfusions must be educated about the indications and risks involved.
Tolerance of low haemoglobin concentrations has been discussed and is the first step toward reducing exposure to HBP. Although the limits of haemodilution remain to be defmed, transfusions guided by clinical indications while allowing the haematocrit to decrease to <25% resulted in fewer RBC requirements, similar exercise tolerance and no adverse clinical consequences compared with transfusions aimed at maintaining the haematocrit above 32% in patients undergoing myocardial revascularization. ~ Autologous blood predonation remains underused, but should be considered before all elective procedures for which blood would be crossmatched normally. Autologous donation decreases the need for HBP in part because physicians tolerate lower haemoglobin concentrations in patients who are autologous donors. 67 Autologous blood is immunologically identical to the recipient and is the safest possible transfusion product. Thus, autologous blood is transfused somewhat more liberally, but it should be administered only when signs or symptoms of anaemia are present to avoid volume overload and hyperviscosity. The risk of administering an incompatible transfusion secondary to a clerical error is always present. A programme for preoperative donation is in place at the Canadian Red Cross Blood Centre's permanent clinic site. 7 Patients may donate a unit of blood weekly for a maximum of four units. All patients may be considered, but specialized centres will be required for high risk donors with severe cardiovascular disease. Autologous units are identified with a specific green "autologous only" tag and should be checked as carefully as for HBP. Currently, these units are not transfused to other patients.
In the absence of predonation, other autologous techniques may still be used. Normovolaemic haemodilution (NH) is effective, save, and easy to implement. 6s Under sterile conditions, blood is withdrawn from a central or large peripheral vein, or an artery, into bags containing anticoagulant. The volume of blood to be removed depends on the patient's estimated blood volume (EBV),. initial haematocrit (Hi) and desired (final) haematocrit (HI), and is calculated as follows:
Hi-Hf Volume to be removed = EBV X --Hm where Hm is the mean of Hi and Hf and allows for correction for ongoing dilution. 69 Normovolaemia must be maintained strictly. Crystalloids or colloids may be chosen, depending on the patient's underlying condition and his capacity to handle fluid shifts. Each unit of blood collected is labeled carefully and kept at room temperature (up to six hours) to preserve platelet function. The blood is reinfused whenever necessary, preferably when major blood loss is controlled. The main contraindication to NH is anaemia. Coronary artery disease does not preclude NH, but ischaemia or haemodynamic instability may limit the volume of blood that can be removed safely.V~ Intraoperative salvage of RBC using automated blood collecting and washing equipment has been shown to be useful in cardiac, vascular, orthopaedic, and trauma surgery. 7l Potential complications are numerous and in-elude coagulopathy when large volumes of washed cells are reinfused. However, the major drawbacks to this technique are the high costs, both in equipment and personnel, required to operate these blood salvaging systems. 6s,7 i
After cardiac surgery, shed mediastinal blood can be collected in the same cardiotomy reservoir used during CPB and retransfused to the patient. While this approach is economical and can contribute to reduced transfusions of RBC, 72 it may become counterproductive when surgeons rely on the technique to the detriment of meticulous haemostasis.
In Canada, blood from friends or relatives selected by a patient for their own use is not collected by the Canadian Red Cross Society. Directed donations are used only for matching of rare blood types or for transfusing platelets to a refractory patient. 7 In the United States, many blood eentres have started designated donor programmes in response to public pressure or state laws, but several arguments militate against the concept: the increased safety of blood obtained from designated donors remains unproven; an additional clerical burden is imposed on the blood banking system; regular blood supplies may decrease if routine donors refrain from donating blood in order to remain available for specific patients. J7 Furthermore, directed donations from family members carry a risk of graft-vs-host disease if the donor is homozygous for an HLA haplotype shared with the recipient. 73 This situation has now also been reported in unrelated donors. 74 Finally, synthetic oxygen transport media are being developed to reduce the requirements for RBC during the perioperative period. 5 These substitutes are not in clinical use and will not be discussed further.
Conclusion
Despite the complications associated with transfusions , HBP remains an essential therapeutic modality, without which many major surgical procedures would be impossible. Clinicians must realize that transfusion of HBP is the most frequent transplantation of living tissue between humans. Even if known infectious complications could be eliminated, transfusion of HBP will never be a totally safe procedure. New transfusion-related complications, the magnitude of which is unknown, such as graft-vshost disease in immunocompetent patients, have emerged recently. Other, as yet unidentified, pathogens will undoubtedly be transmitted by HBP in the future.
A number of strategies exist that can reduce, and sometimes abolish, the need for HBP. Unfortunately, some of these may remain unavailable to our patients because of financial constraints on the Canadian health care system. Nonetheless, physicians must always keep in mind that the first and foremost strategy to avoid transfusion of HBP is their thorough understanding of the pathophysiological mechanisms involved in anaemia and coagulopathy, and their thoughtful adherence to published guidelines for the practice of transfusion. 7,11-13,17 Cette mise ~ jour a pour objeetif: 1) de revoir bri6vement les complications infectienses associres aux transfusions; 2) de rrexaminer les indications des produits sanguins homologues (PSH); 3) de discuter des stratrgies alternatives offertes pour diminuer ou 6viter les transfusions de PSH. Une attention particulirre sera accordre au problrme canadien.
Du bon usage des drrivrs du sang

Les complications infeetieuses de la transfusion
Les complications provoqu6es par le sang homologue ont d6jA donn6 lieu /t de nombrenses publications 3,4 et apparaissent au Tableau I. Le risque infectieux des transfusions s'est att6nu6 ces derni6res ann6es grfice aux politiques de d6pistage du donneur (Tableau II) introduites par le service de transfusion de la Soci6t6 Canadienne de la Croix-Rouge. 7 En g6n6ral, la contamination bact6rienne ne pr6sente pas de probl6me, except6 pour les pr6parations de plaquettes qui sont stock6es /l la temp6rature de la pi6ce ou en pr6sence du Yersinia enterolitica pour lequel la temp6rature de 4~ n'a pas la m~me efficacit6 bact6riosta-tique que pour les autres bact6ries. Au Canada, les parasites ne cansent pas de probl6me s6rieux. Les infections les plus fr6quentes associ6es aux transfusions de produits sanguins homologues demeurent l'h6patite post-transfusionnelle (HPT): le virus de l'hrpafite A, le cytomrgalovirus et le virus d'Epstein-Barr transmettent rarement I'HPT. Aux E.U.A., la frrquence de rHPT transmise par le virus de llarpatite Best 6valure h I sur 50,000 receveurs ou 1 sur 200,000 unitrs transfusres, s Quatre-vingt-dix pour cent des cas (dont la majorit6 est asymptomatique) 6voluent spontanrment vers la gu&ison, cinq h dix pour cent vers la chronicit6 (dont la moiti6 deviendront des porteurs asymptomatiques) ou vers une hrpatite fulminante (avec un taux de mortalit6 plus 61ev6 que 50%). Les statistiques canadiennes sort identiques. Au tours des trois dernirres annres, le centre de transfusion de Montrral n'a rapport6 qukm seul cas d'hrpatite B posttransfusionnelle (communication de Gilles Delage du centre de Montrral de transfnsion de la Socirt6 Canadienne de la Croix-Rouge). Si on assume, que seulement 25% des infections sont symptomatiques, on obtient un taux d'infection identique ~i celui des US.
Le virus de l~arpatite C (HCV) est ragent responsable de la plupart des HPT non A-non B, mais pas de toutes. Comme pour l~rpatite B, l'incidence d'HPT associre au HCV varie selon la population 6tudire. Au Canada, le taux d~mfection est le mOme qu'aux USA (communication personnelle, Gilles Delage), c.-~t-d, environ 1 sur 3,000 produits sanguins transfusrs. 9 L~rpatite C posttransfusionnelle se manifeste initialement de fa~on brnigne mais 50% des patients 6voluent vers la chronicit6 (rtat du porteur persistant) et de 10 /t 20% de ceux-ci developpent une cirrhose.
En 1992, Crosby rapportait qu'au Canada, depuis l'implantation des mesures de drpistage en 1985, settlement deux conversions probables au VIH (sur 15 milliom d'unitrs de produits sanguins administrrs) ont 6t6 associres aux transfusions. 3 Les mesures nsuelles de drpistage consistent/~ drtecter les anticorps du VIH. En moyenne, ces anticorps sont nrgatifs pendant huit semaines aprrs 15nfection mais la srro-conversion peut survenir aussi tardivement qu'aprrs 42 mois. De l/t, la possibilit6 que quelques unitrs contaminres puissent 6ehapper ~t la drtection systrmatique des antieorps du VIH. l0 Toutefois,, grg~,e ~t la srlection actuelle des donneurs et aux tests sanguins, le risque de transmission du VIH par transfusion sanguine se situe entre 1/40,000 et 1/1,000,000. Ij Le HTLV-I et le HTLV-2 sont associrs ~t la leu~mie, au lymphome, h la parapar~sie spastique tropicale; une myrlopathie est associre au HTLV-1. En Amrrique du Nord, la transmission du HTLV-I est rare et les risques associrs sont difficiles ~ 6valuer.
Tout porte ~t croire qu'environ trois receveurs sur 10 000 contractent une maladie virale grave ou fatale par transfusion sanguine.S Selon la Croix-Rouge canadienne,
TABLEAU I Classification des rtaetions transfusionnelles 3~s
Rdactions antig~nes-anticorps 
Indications de la transfusion des hdmaties (concentrd ~rythrocytaire)
Les concentr6s 6rythrocytaires sont pr6par6s en soutirant apr~s centrifugation le plasma qui surnage le sang complet. Un sac de culot contient 200 ml de globules rouges avec de l'anticoagulant CPDA-1 ou de ranticoagulant CP2D et 100 ml d'additif AS-3 (Nutricel@), et 90 ou 60 ml de plasma. La survie de stockage est de 35 jours 1~176 mais les culots contenant de i'AS-3 ont un potentiel de survie de 42 jours. On peut ajouter du solut6 physiologique isotonique ~t ces pr6parations pour augmenter le d6bit des 6rythrocytes. Les concentr6s 6rythro-cytaires doivent &re administr6s ~ travers un fdtre de 170 ~t.
La Conf6rence reconnalt qu'aucune 6vidence ne supporte l'utilisation d'un seul crit~re transfusionnel, tel que un taux d'h6moglobine <100 g-L-L ~ La d6cision de transfuser un patient doit tenir compte de la dur6e de l'an6mie, du volume circulant, de la complexit6 de l'intervention, de la probabilit6 de pertes sanguines importantes et de la pr6sence de conditions co-existantes comme une alt&ation de la fonction respiratoire, une insuffisance du d6bit cardiaque, une isch6mie myocardique ou une affection c~r6brovasculaire ou vasculaire p~riph6ti-que ~. ~ Comme r6nonce la Conf6rence, les indications de la transfusion d'6rythrocytes sont encore mal d6finies et des recherches devraient permettre de les d&erminer. Alors tt qu'aucune mesure unique ne remplace le bon jugement clinique comme base de d6cision au regard des transfusions p~tiop6ratoires ~, est-il possible de perfectionner nos crit+res de transfusion d'6rythrocytes? L'6rythrocyte a pour fonction de transporter et de lib6rer aux cellules l'oxyg~ne alv6olaire. Lors dkme perte sanguine aigu/% on admet g6n6ralement que la restauration de la vol6mie est plus importante que la composition du fiquide de remplacement. Ainsi, les 6rythrocytes ne devraient pas ~tre administr6s pour remplacer le volume perdu, mais seulement pour traiter l'an6mie et la baisse de capacit6 de transport de roxyg6ne du sang associ6e h l~a6morragie grave. La transfusion de concentr6 6rythrocytaire est alors utilis6e pour augmenter l'apport en oxyg6ne aux tissus. L'augmentation anormale de rindex cardiaque et de la consommation d'oxyg6ne sont aussi des facteurs d6terminants de survie lors du choc septique ou h6morragique. ~ Pendant l'h6modilution normovolSmique (ran6mie sans hypovol6mie), la viscosit6 sanguine diminue et la DO2 demeure relativement constante entre des valeurs R65 de 500 ml h plus de 2000 ml malgr6 le maintien d'une volrmie adrquate.2~
Comme le contenu en oxyg~ne du sang n'est pas le seul drterminant de la DOE et de la x/O2, l'efficacit6 de la transfusion des concentrrs 6rythrocytaires doit ~tre monitorre. Il est intrressant de noter que, chez le chien, i'hrmodilution modrrre jusqu'/l un hrmatocrite de 20 ou 30% est associ~e ~ une amtlioration de la capacit6 d'extraction systdmique de 1'O2 (une DO 2 critique plus basse et un REO2 critique plus 61ev6 pendant llatmorragie), comparativement h l~atmorragie abaissant l'htmatocrite 40%. 29 La rtponse de la VO2 h radministration de concentrts 6rythrocytaires constitue un bon crittre de justification. L'ineonvtnient pratique de cette recommandation vient du fait que la mesure de la x/O~ exige un monitorage htmodynamique effractif. Cependant, l'augmentation de la lactastrnie indique avec prtcocit6 l'insuffisance de la perfusion et met en 6vidence la dette en oxygtne. Avec les analyseurs de gaz sanguins automatists, la lactastmie est mesurable instantantment et procure un ttmoignage non effractif du mttabolisme anatrobique. Une augmentation subite de la lactastmie est observte quand la DO2 diminue sous la valeur critique. 2~ Ainsi, au moins dans un sous-groupe de patients, la lactastmie peut devenir un indicateur utile pour dtterminer la pertinence des transfusions de concentr6 6rythrocy-taire. 22 Une autre fonction moins connue des globules rouges consiste ~ augmenter rinteraction interplaquettaire et faciliter rinteraction des plaquettes avec la membrane basale de rendothtlium. La transfusion d'trythrocytes normalise le temps de saignement des antmiques thrombocytoptniques malgr6 une thrombocytoptnie persistante. 23 De la mSme fa~on, les htmaties contr61ent la tendance htmorragique de rantmique et abrtgent son temps de saignement. 24 Toutefois, un taux d'htmoglobine acceptable pour le maintien de la DO 2 peut ~tre insuffisant pour procurer une htmostase optimale. Ceci peut aider ~t expliquer pourquoi, aprts CEC, reffet htmostatique dkme seule unit6 de sang frais est au moins 6gale, sinon suptrieure ~ dix unit~s de plaquettes. 25 Indications de la transfusion de plaquettes 7,13.1z Dans le contexte de l'anesthtsie et de la chirurgie, les concentrts plaquettaires sont les deuxitmes produits sanguins les plus utilists aprts les 6rythrocytes. Les plaquettes sont concentrtes dans 30-50 ml de plasma et le produit final contient un petit hombre de leucocytes et d'h~maties (jusqu'~ 0.4 ml par unit~). Le stockage ~ la temptrature de la pitce (200-24 ~ C) prtserve la fonction et une agitation lente et continuelle prtvient la formation d'aggrtgats. On limite le stockage h deux jours pour 6viter la croissance bacttrienne. Chez radulte normal, une unit6 de concentr6 plaquettaire augmente le dtcompte par 5-10 )< 10 9. L -~ une heure aprts son administration. Ainsi, la dose usuelle est de six h huit unitts, ce qui expose le receveur h autant de donneurs. Les unitts de plaquettes peuvent 6tre mtlangtes dans un seul sac avant radministration qui doit se faire en-de~h de six heures. Lhtilisation d~an ffltre de 170 ~tm est recommandte. I1 est accept~ d'administrer des plaquettes incompatibles ABO. MSme avec des plaquettes compatibles ABO, une immunisation Rh chez les femmes en ~ge de porter des enfants est toujours possible. Dans certaines circonstances, on peut ~tre fore6 dhtiliser des plaquettes de donneurs uniques au hasard ou typts pour le HLA.
Les thrombocytoptniques graves peuvent btntfieier de transfusions de plaquettes pour la prtvention de llatmorragie. En milieu hospitalier, on considtre gtntralement la valeur empirique de 20 • 10 9. L -1 plaquettes comme adtquate. Les thrombocytoptniques chroniques n'ont gtntralement pas besoin de transfusion systtmatique de plaquettes mais peuvent btntficier de radministration prophylactique de plaquettes avant la chirurgie ou d'autres manoeuvres effractives. On suggtre une consultation en htmatologie pour d&erminer individuellement la num6ration optimale pour chaque patient. D'autres mesures comme l'administration /v d'immunoglobines peuvent normaliser le dtcompte dans le purpura thrombocytoptnique idiopathique.
En rtgle gtntrale, les produits sanguins administrts pour l'htmostase, comme les concentrts de plaquettes et le PFC, ne devraient jamais l'~tre en absence de saignement sur la foi des seuls tests de laboratoire. Les thrombtcytoptniques ou tous les patients dont la fonction plaquettaire est anormale et qui saignent, ne devraient en recevoir que si on croit que la dtficience plaquettaire cause le saignement ou y contribue. 33 I1 est possible d'obtenir trts rapidement une numtration plaquettaire raisonnablement prtcise avec un compteur automatique. En absence de dysfonction plaquettaire, on ne peut tenir responsable d'un saignement actif un dtcompte de 50 X 10 9. L -! OU plus. La fonction plaquettaire est beaucoup plus difficile h 6valuer et jusqu'~ maintenant, on n'a pas identifi6 la mtthode idtale de le faire. L'apparence de la plaie chirurgicale, le temps de saignement avec ttmoin, le thrombotlastogramme, et l'analyse avec le Sonoclot Signature| peuvent fournir une apprtciation valable de la fonction plaquettaire.
La transfusion massive est dtfinie ordinairement par l'administration rapide de rtquivalent du volume sanguin dans une intervalle de quelques heures. Elle peut conduire une coagulopathie caracttriste par du saignement micro-vasculaire (suintement typique gtntralist) aprts 15-20 unitts de concentr6 6rythrocytaire chez un adulte jusque 1~ ~ bien portant ~.26,27 Par ordre de frtquence, les coagulopathies rtsultent: 1) de la perte de plaquettes, et tr~s rarement, des facteurs labile Vet VIII; 2) de la coagulation intravasculaire disstminte (CIVD) associte au choc; et 3) de rtactions transfusionneUes htmolytiques. ~3 La liberation par la rate et la moelle osseuse de plaquettes aide/~ prtvenir la thrombocytoptnie dilutionnelle mais en prtsence de saignement microvasculaire, un d~ompte plaquettaire/~ 50-100 • 10 9. L -~ constitue une indication pour la transfusion de plaquettes. 26.27
Les indications de transfuser des plaquettes apr~s la CEC ne different pas et on n'est jamais justifi6 de les administrer prophylactiquement aux patients qui subissent une intervention cardiaque/t coeur ouvert.
Quand le saignement ne tarit pas aprts des transfusions adtquates de plaquettes, le prochain choix logique consiste/~ administrer du plasma frais congelt. 28 
Les indications du PFC z'lzt7
Apr~s la s*parafion des plaquettes, ce qui reste du plasma est congel6 rapidement pour prtvenir l'activation des facteurs de coagulation thermosensibles (~ labiles ~>) Vet VIII. Lhnit6 de PFC, de 190-260 ml en volume, est stockte/t la temptmture de -18~ Le PFC a peu d'indications sptcifiques. I1 n'est pas justifi6 dMtiliser le PFC pour le remplissage vasculaire et les besoins de la nutrition. On n'a jamais prouv6 que l'administration de PFC avait sa place dans le traitement des hemorragies massives. Le PFC contient tous les facteurs plasmatiques de coagulation hun niveau d'activit~/t peu pros normal. I1 est indiqu6 dans le traitement de dtficits en facteurs quand la th~mpie sp~cifique n'est pas disponible ou inapproprite. Dans ce contexte, la recommandation de la meilleure thtmpie viendra de la consultation htmatologique.
Les dtficits fonctionnels induits par les anticoagulants oraux peuvent ~tre renvers~es par la vitamine K. Comme la vitamine K sous-cutan~e met de 6/~ 24 heures pour neutraliser les effets des anticoagulants, on utilise le plasma frais congel6 pour une htmostase rapide en eas d'un saignement actif ou d'une chirurgie urgente.
Le plasma frais congel6 peut Etre utilis6 chez les transfusts massifs qui. saignent activement quand un dtficit des facteurs de la coagulation est reconnu comme la cause du saignement. Cependant, dans cette situation, les eliniciens doivent considtrer la thrombocytoptnie comme la cause la plus frtquente de l~atmorragie. La conftrence de consensus admet que dans certaines circonstances, le PFC peut avoir une valeur thtrapeutique (ex. dtficiences multiples en prottines de coagulation lors d'une htmorragie incontr61able) mais les preuves de son efficacit6 sont vagues ou non reconnues. L'administration prophylactique de PFC chez le polytransfus6 n'a pas fait ses preuves non plus.
Finalement, le PFC peut servir comme source d'antithrombine III, pour le traitment des immunodtfieiences sptcifiques et pour le traitement du purpura thrombocytoptnique. Lors dhn saignement actif, lorsque le PFC est indiqut, l'administration rapide de grands volumes (quatre/l huit unitts) est ntcessaire pour produire une augmentation notable de la concentration des facteurs de coagulation. 29 En absence de saignement actif, deux unitts de PFC suffisent pour renverser l'effet de la warfarine ou de la coumadine en cas de besoin. Cependant, cet effet n'est que transitoire (six A huit heures) et une r~currence de la coagulopathie est A craindre si on n'a pas administr6 de vitamine K.
Comment ~viter les produits sanguins homologues
Plusieurs strattgies sont recommandtes darts le but de diminuer et m~me de supprimer les transfusions de PSH (Tableau IV). Certaines sont inoffensives mais d'autres comportent des risques qui doivent ~tre pests chaque fois qu'on administre un PSH.
Strategies prEop~ratoires
Les anti-inflammatoires non sttro'idiens (AINS), 3~ l'acide acttylsalicylique (ASA), a~ et possiblement quelques inhibiteurs calciques sont associts au saignement perioptratoire; avant une chirurgie r~glte, ils devraient ~ti-e discontinuts ou du moins remplaets lorsque possible par des produits ~t derni-vie plus courte.
Etant donn6 les risques entralnts par l'administration des PSH, on a suggtr6 d'obtenir un consentement 6clair6 avant les transfusions, 37 mais on ne s'entend pas sur une forme du consentement verbal ou 6crit. ~7 L'anesthtsiste dolt toutefois toujours inscrire au dossier d'anesthtsie ses indications pour l'administration de PSH. 17 En Californie, le Paul Gann Blood Safety Act rend obligatoire la notification du risque transfusionel et de ses alternatives. Cette loi semble avoir polaris6 l'attention sur les mtthodes de conservation du sang eta provoqu6 une baisse du nombre de transfusions de PSH en chirurgie cardiaque. 38 Certaines strategies peuvent att~nuer les pertes sanguines peropEratoires. On eonnalt dtj~t plusieurs techniques qui permettent de diminuer les pertes sanguines pendant la chirurgie. Elles comprennent l'utilisation du garrot, l'inffltration d'anesthtsiques locaux adrtnalints, le drainage veineux du site optratoire, llaypotension contr616e mais surtout l'htmostase mtticuleuse pratiqu~ par le chirurgien. On a aussi montr6 qu'en chirurgie cardiaque le contrble du stress favorisait l'htmostase, mais son influence sur les pertes sanguines et les besoins transfusionnels n'est pas prouv~e. 39 Le maintien de la normothermie constitue pour llatmostase un 616ment important quoique souvent oublit. L'hypothermie provoque une dysfonction plaquettaire rtversible; aprts la CEC, le rtchauffement rttablit la fonction plaquettaire, abrtge le temps de saignement et diminue la perte sanguine. 4~ On conseille de rtchauffer le patient hypothermique avant de lui administrer des PSH, que ce soit apr~s la CEC ou un traumatisme. 4~ De plus, l~ypothermie inhibe fortement les r~actions enzymatiques de la cascade de la coagulation; comme les gpreuves de coagulation sont r~alis6es/l 37~ on peut facilement oublier la contribution de l'hypothermie :~ la coagulopathie. 4~ Le traitement pharmacologique de l~a6morragie surtout aprts la CEC, attire de plus en plus attention. 42 L'administration prophylactique de I'EACA et du TA a surtout 6t6 limitte/l la chirurgie cardiaque et ~ la chirurgie mineure de Hatmophile. Des donntes r&rospectives recueillies chez 411 patients du Toronto Hospital montrent que le TA/l la dose de 10 g diminue le saignement post-CEC des 24 heures initiales, prtvient le saignement excessif (>750 ml en six hems) et rtduit le pourcentage des patients qui re~oivent des PSH. s2 D'autres donntes fournies par la mSme institution montrent que le TA, I'EACA et la perfusion normothermique sont tous aussi efficaces pour diminuer Hatmorragie postoptratoire et conserver les plaquettes.S3 Sans donntes suppltmentaires, on ne peut prtsentement dtterminer en chirurgie cardiaque la posologie optimale et l'efficacit6 de ces drogues. L'EACA et le TA ont la m~me efficacit6 pour traiter la fibrinolyse et contrtler le saignement associts ~ la transplantation htpatique, bien qu'on ne puisse recommander lhasage universel de ces produit ~t cause du danger de thrombose. 54 L'aprotinine est un polypeptide form6 des rtsidus de 58 acides amints qui inhibe un vaste spectre de prottases. En plus de l'activit6 antiplasmine (antifibrinolytique) qu'elle partage avec rEACA et le TA, raprotinine inhibe l'activation de la kallicrtine et la cascade de la coagulation secondaire/t la libtration de ractivateur du plasminogtne tissulaire. Cette double action est, semble-t-il, responsable pour son efficacit6 gtntralement reconnue en chirurgie cardiaque.42 L'aprotinine a 6t6 aussi ufiliste avec succ~s dans rhtmatome rttro-placentaire compliqu6 dhne coagulation intravasculaire disstminte, 55 pour la prtvention de la r~currence du saignement apr~s laatmorragie sousarachnoidienne 56 et pour le contrtle du saignement orthoptdique (communication personnelle du Dr John Murkin) et vasculake chirurgical.57 Dans plusieurs centres, on administre systtmatiquement comme mesure prophylactique de l'aprotinine ~ haute dose (dose de charge deux millions de KIU, suivie d'une peffusion de 500 000 KIU. h-~); administrte de cette fa~on, l'aprotinine diminue le saignement ptrioptratoire et les besoins en PSH pendant la transplantation htpatique ss,S9 et la chirurgie cardiaque (on ajoute deux millions KIU h ramorce de la CEC). 60 L'administration d'aprotinine peut provoquer des rtponses allergiques mineures ou de l'anaphylaxie, sptcialement si on la rtptte mais le risque de ces complications est minime (<1%). 61 Malgr6 les craintes que de fortes doses d'aprotinine puissent augmenter les complications thrombotiques, le bilan de raprotinine est jusqu'~ maintenant impressionnant sous l'aspect de la S~CUrit~. 62, 63 Les mesures qui diminuent l'incidence de l'an~rnie Ces mesures ont bien connues des anesthtsistes et il n'est pas ntcessaire d'en faire la description ici. Elles permettent d'atttnuer les constquences physiologiques de ran6mie pendant qu'on confirme la ntcessit6 de recourir aux transfusions.
Les alternatives au sang homologue ?t la p~riode p~riop~ratoire Malgr6 tous nos efforts de prtvention, la transfusion de concentr6 6rythrocytaire peut devenir ntcessaire. Encore 1~, nous disposons de strattgies d'tconomie du sang homologue. D'abord, ceux qui prescrivent les transfusions ne devraient le fake qu'apr~s mf~re rtflexion et devraient 6viter de rtagir automatiquement comme s'il s'agissait d'un stimulus physiopathologique. L'attention port~ une batterie de crittres arbitraires pluttt qu'aux besoins du patient explique la grande variabilit6 de la pratique transfusionnelle en chirurgie cardiovasculaire. 64 ~t Les patients savent que cette pratique est inacceptable; il nous faut aussi le reconnaitre. Le sang et ses dtrivts ne doivent 8tre administrts que lorsque l'indication en est certaine ~>.65 I1 s'ensuit donc que ceux qui prescrivent des transfusions doivent en connaRre parfaitement les indications et les risques.
La toltrance de l'organisme aux basses concentrations d~tmoglobine a 6t6 6tudite et constitue un premier pas vers la diminution des transfusions de PSH. Bien que les limites de l'htmodilution soient encore ~ dtfmir, les transfusions guidtes par des indications cliniques valides et une baisse en de l'htmatocrite sous le niveau de 25%, ont fait diminuer les besoins en globules rouges chez des patients soumis ~ une revascularisation myocardique; on a constat6 chez ces patients la mSme toltrance ~ l'exercice et l'absence de constquences nocives, lorqu'on les comparait h d'autres dont lla~matocrite ~tait maintenu hun niveau plus 61ev6 que 32%. 66 Les prtltvements de sang autologue demeurent sousutilists mais devraient ~tre considtr~s avant toutes les interventions pour lesquelles on a l'habitude de fake des 6preuves de compatibilitt. Les dons de sang autologue diminuent les besoins en PSH en pattie parce que les mtdecins toltrent des concentrations plus basses d]atmoglobine chez le donneur autologue. 67 Le sang autologue est immunologiquement identique au sang du receveur et offre pour la transfusion la plus grande stcurit6 qui soit. On a donc tendance ~ transfuser le sang autologue sans retenue mais aim d'tviter la surcharge et l'hyperviscosit~ on ne le devrait le fake qu'en cas d'antrnie. Le risque d'administrer un sang incompatible en raison dhne erreur d'identification est toujours prtsent. Un programme de prt-dons est en place aux cliniques permanentes de transfusion de la Croix-Rouge. 7 On peut fournir une unit6 de sang par semaine jusqu'~t un maximum de quatre unitts. Tous les patients sont acceptables, mais ceux qui sont h haut risque comme les malades cardiaques graves doivent s'adresser ~ des centres sptcialists. Les sacs de sang autologues sont identifi~s avec une 6ti-quette verte et doivent 8tre v~rifits comme s'ils contenaient des PSH. Pr~sentement, ce sang n'est pas transfus6 ~t d'autres receveurs.
Sans dons pr~alables, on peut utiliser le sang autologue sous d'autres formes. L'htmodilution normovoltmique (HN) est efficace, sans danger et facile h rtaliser. 68 Sous des conditions sttriles, le sang pr~lev6 par une grosse veine ptriph~rique ou une art~re est recueilli dans des sacs contenant de l'anticoagulant. Le volume de sang ~t retker d~pend du volume sanguin estim6 du patient (VSE), de l'htmatocrite initial (Hi) et de l'htmatocrite final (HI') et se calcule comme suit:
Hi-Hf Volume ~t pr~lever = VSE • --Hm off Hm est la moyenne de Hi et Hf, ce qui permet de falre la correction pour la dilution en tours.69 Une normovoltmie stricte doit 8tre maintenue. On peut remplacer soit avec des colloYdes, soit avec des critallo'ides selon la condition du patient et sa capacit6 de toltrer des 6changes hydrotlectrolytriques importants. Chaque unit~ recueillie est ~tiquett~e et gardte ~ la temptrature de la pitce pendant un maximum de six heures pour conserver la fonction plaquettaire. Le sang est retourn6 la circulation au moment approprit, de prtftrence une fois l'htmorragie contrtlte. La principale contre-indication de I'HN est l'antmiel mais l'ischtmie ou l'instabirit6 htmodynamique limitent la quantit6 de sang qui peut 8tre prtlevte sans danger. 70 La rtcuptration peroptratoire des htmaties par aspiration et lavage automatists s'est avtrte utile pendant la chirurgie cardiaque, vasculaire, orthoptdique et traumatologique. I7 Les complications potentielles sont nombreuses dont la coagulopathie lorsque de grands volumes de cellules lavtes sont reperfusts. Cependant, les dtsavantages majeurs de cette technique sont constituts par les cofits, tant en 6quipement qu'en personnel, ntcessaires au fonctionnement de ces systtmes de rtcuptration. 68, 71 Aprts une chirurgie cardiaque, on peut receuillir le sang mtdiastinal dans le rtservoir de cardiotomie utilis6 pendant la CEC et le retransfuser au patient. Cette approche est 6conomique et contribue ~ la diminution du nombre de transfusions, 72 mais eUe devient ntfaste quand le chirurgien fait contiance ~ cette technique au dttriment d'une l'htmostase chirurgicale soignte.
Au Canada, la Socitt6 Canadienne de la Croix-Rouge ne receuiUe pas le sang des parents et amis rtftrts par le patient pour son usage propre. Les dons de sang dirigts ne sont utilists que pour la compatibilit6 des types sanguins rares ou pour transfuser des plaquettes hun patient r~fractaire. 7 Aux Etats-Unis, plusieurs centres de transfusions ont initi6 des programmes de donneurs dtsignts sous la pression de l'opinion pubrique ou des lois de certains 6tats, mais plusieurs arguments militent contre ce concept; on n'a pas prouv6 que le sang de donneur dtsign6 offrait une plus grande stcuritt; un fardeau cltrical suppltmentaire est impost aux banques de sang; les approvisionnements rtguliers de sang peuvent se tarir si les donneurs rtguliers cessent d'alimenter les banques pour pairier ~t des besoins sptcifiques. 17 De plus, les dons dirigts familiaux comportent le risque d~ane rtaction greffon contre lla6te si le donneur est homozygote avec un haplotype HLA partag6 avec le receveur. 73 On a aussi rapport6 cette complication chez des donneurs non apparentts. 74 Finalement, pour diminuer lklsage des 6rythrocytes la ptriode ptrioptratoire, on pourra 6ventuellement utiriser les succtdants transporteurs d'oxyg~ne. 5 Comme ces substituts ne sont pas encore utilists en clinique, ils ne font pas partie de la prtsente discussion.
sions de PSH ne deviendront jamais compl~tement inoffensives. De nouvelles complications transfusionnelles comme la rtaction du greffon contre l'htte chez des patients immunocompttents ont fait rtcemment leur apparition. A ravenir, d'autres pathog+nes, non encore identifits seront indubitablement transmis par les PHS.
Certaines strattgies peuvent diminuer et quelquefois abolir les besoins de PHS. Malheureusement, quelquesunes ne sont pas disponibles pour nos patients h cause des contraintes du syst+me des soins de sant6 canadien. Toutefois, les mtdecins doivent toujours avoir h l'esprit que la premiere et la principale strattgie permettant d'tviter les PHS consiste en une bonne comprthension des mtcanismes physiopathologiques impliquts dans l'antmie et les coagulopathies et leur adhtrence incondifionnelle aux crittres de la pratique transfusionnelle. 7j [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 17 R~f~rences (Voir page R59)
Conclusion
Malgr6 les complications assocites aux transfusions, les PSH demeurent essentiels et sans eux plusieurs interventions chirurgicales majeures seraient irrtarisables. Les criniciens doivent rtariser que les transfusions de PSH reprtsentent les transplantations de tissus les plus frtquentes entre humains, et que m~me si on rtussissait ~t 61iminer complttement les complications infectieuses, les transfu-
